Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2009. The announcement, issued on January 29, 2009, addresses a significant legal charge to be recorded in the fourth quarter of 2008. GSK is a leading research-based pharmaceutical and healthcare company.
Key Financial Metrics
- Legal Charge (Q4 2008): $400 million (£278 million) related to a US investigation into marketing practices from 1997 to 2004.
- Total Expected Legal Charge (Q4 2008): £517 million (compared to £62 million in Q4 2007).
- Total Expected Legal Charge (Full Year 2008): £611 million (compared to £255 million in FY 2007).
- Earnings Guidance (2008): Excluding the new charge, performance remains in line with a previously announced mid-single digit percentage decline in business performance EPS at constant exchange rates.
- Cash Flow, Revenue, and Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes Versus Prior Period
The most significant change is the substantial increase in legal provisions. The total legal charge for the full year 2008 is projected to be £611 million, a sharp increase from £255 million in 2007. Similarly, the Q4 2008 legal charge of £517 million represents a significant rise from the £62 million recorded in Q4 2007. This new £278 million charge was not included in the assumptions used for the company's 2008 earnings guidance.
Guidance, Outlook, and Risks
- Outlook: Management states that excluding the new legal charge, the company's performance remains consistent with its guidance of a mid-single digit decline in 2008 EPS at constant exchange rates.
- Contingencies: The ultimate liability regarding the US Attorney's Office investigation may vary from the provided amount depending on the outcome of the investigatory process and potential litigation.
- Risks: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties described in the 2007 Annual Report on Form 20-F.
- Upcoming Events: GSK will announce its full year results for 2008 on February 5, 2009.
Investor Verification Checklist
- Verify the impact of the £278 million legal charge on the final 2008 EPS when full year results are released on February 5, 2009.
- Monitor the status of the US Attorney's Office investigation in Colorado regarding marketing practices from 1997 to 2004.
- Confirm whether the "mid-single digit" EPS decline guidance holds true after the inclusion of the total £611 million legal charge.
- Review the 2007 Annual Report on Form 20-F for detailed risk factors affecting operations.